BR112018069937A2 - derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf - Google Patents

derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf

Info

Publication number
BR112018069937A2
BR112018069937A2 BR112018069937A BR112018069937A BR112018069937A2 BR 112018069937 A2 BR112018069937 A2 BR 112018069937A2 BR 112018069937 A BR112018069937 A BR 112018069937A BR 112018069937 A BR112018069937 A BR 112018069937A BR 112018069937 A2 BR112018069937 A2 BR 112018069937A2
Authority
BR
Brazil
Prior art keywords
disorders
modulators
imidazole derivatives
tnf activity
hexacyclic
Prior art date
Application number
BR112018069937A
Other languages
English (en)
Inventor
Tracey Horsley Helen
Paul Heer Jag
Keyaerts Jean
Louis Robert Deligny Michaël
Jadot Sophie
De Haro Garcia Teresa
Original Assignee
Sanofi Sa
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Ucb Biopharma Sprl filed Critical Sanofi Sa
Publication of BR112018069937A2 publication Critical patent/BR112018069937A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

uma série de derivados de benzimidazol hexacíclico fundido substituído, e análogos do mesmo, sendo moduladores potentes da atividade de tnfa humano, são consequentemente de benefício no tratamento e/ou prevenção de várias doenças humanas, incluindo distúrbios autoimunes e inflamatórios; distúrbios neurológicos e neurodegenerativos; dor e distúrbios nociceptivos; distúrbio cardiovasculares; distúrbios metabólicos; distúrbios oculares; e distúrbios oncológicos.
BR112018069937A 2016-04-01 2017-03-31 derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf BR112018069937A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163577 2016-04-01
PCT/EP2017/057768 WO2017167995A1 (en) 2016-04-01 2017-03-31 Fused hexacyclic imidazole derivatives as modulators of tnf activity

Publications (1)

Publication Number Publication Date
BR112018069937A2 true BR112018069937A2 (pt) 2019-02-05

Family

ID=55650325

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069937A BR112018069937A2 (pt) 2016-04-01 2017-03-31 derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf

Country Status (8)

Country Link
US (1) US10766906B2 (pt)
EP (1) EP3436456B1 (pt)
JP (1) JP6968089B2 (pt)
CN (1) CN109219609B (pt)
BR (1) BR112018069937A2 (pt)
CA (1) CA3018992A1 (pt)
EA (1) EA201892144A1 (pt)
WO (1) WO2017167995A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CN113227097B (zh) * 2018-10-24 2023-09-08 Ucb生物制药有限责任公司 作为tnf活性调节剂的稠合五环咪唑衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523669A (ja) 2003-03-10 2006-10-19 ファイザー・インク Ｎｉｍａ調節タンパク質（ｐｉｎ１）を阻害するための、リン酸／硫酸エステル化合物および医薬組成物
TW200615273A (en) * 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
KR101941420B1 (ko) 2011-06-20 2019-01-23 스페로 트리넴, 인코포레이티드 자이라제 및 토포이소머라제 억제제의 인산에스테르
WO2013186229A1 (en) 2012-06-11 2013-12-19 Ucb Pharma S.A. Tnf -alpha modulating benzimidazoles
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
BR112015000675B1 (pt) * 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2016050975A1 (en) * 2014-10-03 2016-04-07 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives
JP7083358B2 (ja) * 2017-04-25 2022-06-10 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体

Also Published As

Publication number Publication date
JP6968089B2 (ja) 2021-11-17
US10766906B2 (en) 2020-09-08
US20190100526A1 (en) 2019-04-04
EP3436456B1 (en) 2021-11-17
EP3436456A1 (en) 2019-02-06
JP2019512532A (ja) 2019-05-16
WO2017167995A1 (en) 2017-10-05
CN109219609A (zh) 2019-01-15
CA3018992A1 (en) 2017-10-05
EA201892144A1 (ru) 2019-04-30
CN109219609B (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
BR112018069936A2 (pt) derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
BR112017006669A2 (pt) derivados de imidazol pentacíclico fundido
BR112016012997A2 (pt) Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf
BR112014030940A2 (pt) benzimidazóis que modulam tnf-alfa
BR112016012242A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
BR112016013018A2 (pt) Derivados heteroaromáticos bicíclicos fundidos como moduladores de atividade de tnf
BR112016011794A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
BR112016012258A2 (pt) Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf
BR112016011484A2 (pt) Derivados de imidazopirimidina como moduladores de atividade de tnf
BR112016011792A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016013012A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
BR112016012243A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
NZ737399A (en) Ccr2 modulators
BR112016012253A2 (pt) Compostos derivados de imidazol e pirazol, composição farmacêutica e uso dos compostos
MY193524A (en) Diaryl macrocycles as modulators of protein kinases
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
BR112016011789A2 (pt) Derivados de purina, composição farmacêutica compreendendo os mesmos e uso dos mesmos
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf
BR112018069937A2 (pt) derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf
BR112017025601A2 (pt) imidazopirazinas tricíclicas fundidas como moduladoras da atividade de tnf
EA201792686A1 (ru) Производные индазола в качестве модуляторов активности tnf
BR112018069941A2 (pt) derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]